PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This trial compared the efficacy and safety of the first oral glucagon-like peptide 1 (GLP-1) receptor agonist, oral semaglutide, as monotherapy with placebo in patients with type 2 diabetes managed by diet and exercise alone. Two estimands addressed two efficacy-related questions: a treatment policy estimand (regardless of trial product discontinuation or rescue medication use) and a trial product estimand (on trial product without rescue medication use) in all randomized patients. RESEARCH DESIGN AND METHODS: This was a 26-week, phase 3a, randomized, double-blind, placebo-controlled, parallel-group trial conducted in 93 sites in nine countries. Adults with type 2 diabetes insufficiently controlled with diet and exercise were randomized (1:1:1:1) to once-daily oral semaglutide 3 mg, 7 mg, 14 mg, or placebo. The primary end point was change from baseline to week 26 in HbA1c. The confirmatory secondary end point was change from baseline to week 26 in body weight. RESULTS: In the 703 patients randomized (mean age 55 years, 50.8% male, and mean baseline HbA1c 8.0% [64 mmol/mol]), oral semaglutide reduced HbA1c (placebo-adjusted treatment differences at week 26: treatment policy estimand, −0.6% [3 mg], −0.9% [7 mg], and −1.1% [14 mg]; trial product estimand, −0.7% [3 mg], −1.2% [7 mg], and −1.4% [14 mg]; P < 0.001 for all) and body weight (treatment policy, −0.1 kg [3 mg], −0.9 kg [7 mg], and −2.3 kg [14 mg, P < 0.001]; trial product, −0.2 kg [3 mg], −1.0 kg [7 mg, P = 0.01], and −2.6 kg [14 mg, P < 0.001]). Mild-to-moderate transient gastrointestinal events were the most common adverse events with oral semaglutide. Trial product discontinuations occurred in 2.3–7.4% with oral semaglutide and 2.2% with placebo. CONCLUSIONS: In patients with type 2 diabetes, oral semaglutide monotherapy demonstrated superior and clinically relevant improvements in HbA1c (all doses) and body weight loss (14 mg dose) versus placebo, with a safety profile consistent with other GLP-1 receptor agonists.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Therapies shown to positively affect albuminuria and declining eGFR include ACE inhibitors, ARBs, SGLT2is, GLP-1 RAs, and the nonsteroidal mineralocorticoid antagonist finerenone.197,209,239,242,393,423–435”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [424]
In the citing paper
“Empagliflozin and canagliflozin demonstrated reduction in MACE in CVOTs; empagliflozin also demonstrated decreased CV death and all-cause mortality.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [424]
In the citing paper
“Empagliflozin, dapagliflozin, canagliflozin, and ertugliflozin have shown a decrease in hospitalization for HF in their CVOTs.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [424]
In the citing paper
“Dapagliflozin based on the DAPA-CKD RCT424 has received an FDA indication to reduce the risk of sustained eGFR decline, end-stage kidney disease, CV death, and hospitalization for HF in adults with CKD at risk of progression.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [424]
In the citing paper
“Multiple studies have shown renal and CV benefits of SGLT2is239,424–426,444,1052–1054”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [424]
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Statistical Analysis With Missing Data
Lahiff, M., Little, R. J. A., & Rubin, D. B. (1989) · Journal of the American Statistical Association · doi:10.2307/2289883 · Cited by 17,265
Cook, R. J., Dickens, B. M., & Fathalla, M. F. (2003) · Reproductive Health and Human Rights · doi:10.1093/acprof:oso/9780199241323.003.0025 · Cited by 10,769
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationStatistical Analysis With Missing Data
Ghosh, S. (1988) · Technometrics · doi:10.1080/00401706.1988.10488446 · Cited by 4,576
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
International Conference on Harmonisation
Guy, R. C. (2014) · Encyclopedia of Toxicology · doi:10.1016/b978-0-12-386454-3.00861-7 · Cited by 1,478
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389 · cited 2×
“†Severe hypoglycemia was defined according to the American Diabetes Association classification (16) (requiring assistance of another person to actively administer carbohydrateor glucagonor takeother correctiveactions).”
Sorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745 · cited 2×
“The safety profile of oral semaglutide was generally consistent with that reported for subcutaneous semaglutide (19)”
8. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s008 · Cited by 699
Cited by
Items 401–500 of 538
Li, W. (2024) · Qeios · doi:10.32388/fgtlkf · Cited by 2
Doggrell, S. A. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1724952 · Cited by 1
Oral Semaglutide: A Novel Oral Preparation of GLP-1 Receptor Agonist
Mohan, B. P., & Eligar, V. S. (2021) · International Journal of Diabetes and Clinical Research · doi:10.23937/2377-3634/1410146 · Cited by 1
Oral semaglutide improves glycemic control and lowers blood lipids: evidence from a real-world study
Gašparini, D., Čakanić, F., Tufekčić, T., Rasnek, D., Wensveen, F. M., & Wensveen, T. T. (2024) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000312 · Cited by 2
“Randomized controlled trials have indicated that oral semaglutide reduces the cardiovascular risk profile in patients with type 2 diabetes and is effective in lowering blood glucose levels and promoting weight loss [11,21,22].”
InfluentialReal-world Use of Oral Semaglutide in Patients with Type 2 Diabetes in India: A Retrospective Study
Chittawar, S., Suri, S., Garg, A., Gupta, V., Patni, B., Mitra, A., Handral, A., Desai, A., Aggarwal, R., & Goyal, R. (2024) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_31_24 · Cited by 1
Masudo, C., Horii, T., Suzuki, R., & Mihara, K. (2025) · Cureus · doi:10.7759/cureus.80511 · Cited by 1
“While oral semaglutide (O-SEMA) offers convenience, its complex dosing and administration requirements may complicate daily use [8].”
Miller, C. K., Young-Hyman, D. L., Wooldridge, J. S., Piatt, G., & Hawkins, J. (2025) · Clinical Diabetes · doi:10.2337/cd25-0020 · Cited by 1
Sind GLP-1-Rezeptor-Agonisten und SGLT2-Inhibitoren auch im höheren Lebensalter geeignet?
Stüdemann, S., & Engeli, S. (2025) · Diabetologie und Stoffwechsel · doi:10.1055/a-2582-5787 · Cited by 1
Glucagon-like peptide-1 receptor analogues and beyond: emerging obesity pharmacotherapies
Abburi, K., Melson, E., Miras, A. D., & Papamargaritis, D. (2025) · Panminerva Medica · doi:10.23736/s0031-0808.25.05339-x · Cited by 1
Popoviciu, M. S., Reurean‐Pintilei, D., Salmen, T., Rus, M., Ferician, A. C., Sava, C. N., Ardelean, A. I., Moroianu, L.-A., & Stoian, A. P. (2025) · Biomedicines · doi:10.3390/biomedicines13092174 · Cited by 1
“Our data reveals that oral semaglutide demonstrated efficacy in reducing the patients’ BMI, supporting its role as an alternative to injectable therapies, even though it is associated with a slightly lower BWR compared to the injectable formulation, as per previous reports [60].”
Kempf, K., Röhling, M., & Martin, S. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1644442 · Cited by 1
Renna, N. F., Ramirez, E. I., Arrupe, M. F., & Ramirez, J. (2025) · Journal of Hypertension · doi:10.1097/hjh.0000000000004158 · Cited by 1
Seighali, N., Chahkand, M. S. G., Ebrahimzade, M., Arashlow, F. T., Maroufi, S. P., Rahnama, P., Matin, M. H., Javazm, A. K., Ebrahimi, P., Nasir, K., et al. (2026) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-026-01149-5 · Cited by 2
“Semaglutide is a long-acting GLP-1 RAs approved for the management of T2DM and obesity, and is the only drug in this class available in both injectable and oral formulations [12, 13].”
InfluentialMalighetti, M. E., Vescini, F., Carpentieri, M. S., Altomari, A., Turchi, F., Porto, A. D., & Dauriz, M. (2025) · Minerva Endocrinology · doi:10.23736/s2724-6507.25.04376-3 · Cited by 1
New Oral GLP-1 Receptor Agonists: Gliprons
Kim, C. (2025) · NeuroTrials · doi:10.65321/ntta.2025.002 · Cited by 1
Costinescu, R., Tilici, D.-M., Paun, D., Paun, S. C., & Guja, C. (2025) · Journal of Medicine and Life · doi:10.25122/jml-2025-0144 · Cited by 1
Correra, A., Mauriello, A., Cetoretta, V., Maratea, A. C., Riegler, L., Sarno, I. D., Giallauria, F., Guerra, F., Russo, V., & D’Andrea, A. (2026) · Pharmaceuticals · doi:10.3390/ph19020297 · Cited by 3
Ruddiman, K. R., Hong, Y.-R., Ard, J. D., Jones, R., Medcalf, A., Foster, G. D., Alkhaddo, J. B., & Cardel, M. I. (2026) · Obesity · doi:10.1002/oby.70156 · Cited by 1
“Between 2019 and 2021, use of telemedicine rose from 15.4% to 85.9% among US office-based physicians [8].”
InfluentialNakano, Y., Morita, S., Nishi, N., Kita, M., Shimo, N., Takeshima, K., Furukawa, Y., & Matsuoka, T. (2026) · Diabetology International · doi:10.1007/s13340-026-00882-w · Cited by 1
“Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), is widely used for managing type 2 diabetes and obesity [1–3].”
Nahabedian, M. Y., Deva, A. K., Ahmed, D., Fanzio, P. M., & Hammer, J. (2026) · Aesthetic Surgery Journal Open Forum · doi:10.1093/asjof/ojag054 · Cited by 1
Giaccari, A., Borroni, F., Dauriz, M., Gioia, D., Baptiste, P. J., Bisio, A., Lastoria, G., Udupa, K., & Barbagallo, M. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113244 · Cited by 1
Vázquez, S. M., Jiménez-Méndez, C., Asensio, A. P., Silva, E., Delgado, P. R., Fernández, L. G., Concellón, M. D. R. B., de la Mano, J. A. P., Vital, A. G., & Pérez, G. C. (2026) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2026.502562 · Cited by 1
Ojinna, B. T., Tariq, S., Agho, O., Channa, R., & Singh, G. (2026) · Cureus · doi:10.7759/cureus.107970 · Cited by 4
“In contrast, the 3 mg and 7 mg doses of oral semaglutide did not differ significantly from placebo (PIONEER trial) [30].”
Takashima, S., Terui, K., YAMADA, F., & Shimotomai, T. (2026) · Diabetology International · doi:10.1007/s13340-026-00903-8 · Cited by 1
Differential Acute Kidney Injury Profiles of GLP-1RAs and SGLT2is: A Network Meta-Analysis
Liang, C.-S., Hsu, C.-C., Chen, J.-J., Hung, C.-M., Zeng, B., Yang, W.-C., Suen, M., Wang, H.-Y., Carvalho, A. F., Stubbs, B., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27094137 · Cited by 2
Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes
Baragetti, A., & Norata, G. D. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70483 · Cited by 1
Jena, S., Jindal, R., Dutta, D., Kamrul-Hasan, A. B. M., & Mahajan, K. (2026) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2026.22.1.8 · Cited by 2
“14 This real-world evidence has shown the effectiveness of oral semaglutide across wide spectra of patients, which are often underrepresented in RCTs, including elderly individuals, those with long-standing T2D and those on multiple drugs ( Figures 2 and 3 , Supplementary Material 2 [S12-17] ).”
Min, E., Goyette, A., Young, E., Moon, K., Bellini, N. J., & Isaacs, D. M. (2026) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2025-0142 · Cited by 1
Jagtap, N., Golchha, A., Katrevula, A., Asif, S., Rughwani, H., Koduri, K. K., Balenki, P., Kalapala, R., & Reddy, D. N. (2026) · Endoscopy · doi:10.1055/a-2891-4165 · Cited by 1
Chabassier, A., Vittrant, B., Binon, P., Scornet, E., & Josse, J. (2026) · Mayo Clinic Proceedings Digital Health · doi:10.1016/j.mcpdig.2026.100375 · Cited by 1
Lin, C.-H., Hung, P., Chung, M., Wu, L.-Y., & Chung, C. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2026.100645 · Cited by 2
“It has been shown that both liraglutide and semaglutide specifically attenuate development of atherosclerotic plaques in APOE – / – and LDLr – / – mice through an anti-inflammatory mechanism [33], and that semaglutide also can decrease markers of systemic inflammation in patients [34,35].”
Ortiz-Seller, A., Real, J. T., Morcillo, E. J., & Ortiz, J. L. (2026) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2026.08.007 · Cited by 1
Yu, M., Peng, L., Jiang, C., Zhang, X., Li, Q., Zhang, L., Su, X., Zeng, Z., Yan, S., Wang, J., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04651-9 · Cited by 1
Targeting Islet GPCRs to Improve Insulin Secretion
Atanes, P., Ruz‐Maldonado, I., & Persaud, S. J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00050-5 · Cited by 1
Oral delivery of the amylin receptor agonist pramlintide
Sinézia, C., Sisnande, T., Icart, L. P., & Lima, L. M. T. R. (2024) · Peptide Science · doi:10.1002/pep2.24346 · Cited by 1
Oral Anti-Diabetic Semaglutide: A GLP-1 RA Peptide
Kahol, R., Jain, A., Sharma, N., & Mishra, S. K. (2024) · International Journal of Innovative Science and Research Technology (IJISRT) · doi:10.38124/ijisrt/ijisrt24jun1950 · Cited by 1
Fiorese, E. L., & Filho, J. R. A. (2024) · Research Society and Development · doi:10.33448/rsd-v13i11.47456 · Cited by 1
Advancements and challenges in the management of obesity using pharmacotherapy (Review)
Alotaibi, S. S., Eldrehmy, E. H., Albogami, S. M., Alkhedaide, A. Q., & Dahab, O. (2025) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2025.12912 · Cited by 1
Carson, E., Khaleq, F., McDonald, C., Smith, N., & Colon, A. R. (2025) · Cureus · doi:10.7759/cureus.88898 · Cited by 1
“For instance, in the PIONEER trials, oral semaglutide showed a range of weight reductions, from -1.7 kg in the cohort receiving oral semaglutide 3 mg daily over 26 weeks in the PIONEER 1 trial to -4.4 kg in the cohort receiving oral semaglutide 14 mg daily in the PIONEER 4 trial [11,12].”
InfluentialRe-imagining Oral Semaglutide in Routine Clinical Practice: Indian Expert Panel Recommendations
Jagadeesha, A., Saboo, B., WANGNOO, S. K., Gangopadhyay, K. K., Kesavadev, J., Bantwal, G., Kalra, P., Thacker, H. P., & PATANGE, S. A. (2025) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_18_25 · Cited by 1
A one-dimensional semaglutide-GLP-1R-based mini static GIBACPreprint
Li, W. (2024) · Preprints.org · doi:10.20944/preprints202406.0953.v1 · Cited by 1
Li, W. (2024) · Preprints.org · doi:10.20944/preprints202408.1713.v1 · Cited by 1
Was kann ein oraler GLP-1-Rezeptoragonist leisten?
Pampel, S. L. (2019) · Info Diabetologie · doi:10.1007/s15034-019-1547-x
Oral Glucose-Lowering Agent Treatments in Type 2 Diabetes Mellitus
İmamoğlu, Ş. (2021) · Turkish Journal of Internal Medicine · doi:10.46310/tjim.815794
Los arGLP1: una oportunidad para el tratamiento del riesgo cardiometabólico
Miramontes‐González, J. P. (2021) · doi:10.52102/contexto_epidemiologico/art-3
Studying the interactions of IT/IS and human resource management in multicultural societies.
Siakas, K. V., & Georgiadou, E. (2003)
A semaglutida oral irá substituir a cirurgia metabólica? Revisão sistemática
Guimarães, A. P. S. E. S., Sendin, A. L., & Campolina, C. D. O. C. (2022) · STUDIES IN HEALTH SCIENCES · doi:10.54022/shsv3n2-009 · Cited by 1
Semaglutide: A Strategic Weapon for Primary Care
Jain, A. (2022) · The Singapore Family Physician · doi:10.33591/sfp.48.3.u3
Estimands in clinical drug development: from design to regulatory assessment
Mitroiu, M. (2022) · Utrecht University Repository (Utrecht University) · doi:10.33540/723
A korai erélyes glikémiás kontroll jelentősége 2-es típusú cukorbetegségben
Hosszúfalusi, N. (2022) · Diabetologia Hungarica · doi:10.24121/dh.2022.s1.2
Суплотова, Л. А., Fedorova, A. I., Kulmametova, D. S., Сергеевна, Д. Т., & Makarova, O. B. (2023) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2022-16-23-148-155
GLP -1 agonists for weight loss: What you need to know
Goldberg, J. F. (2023) · Current Psychiatry · doi:10.12788/cp.0318
Beneficios cardiovasculares del semaglutide: un nuevo agonista del GLP-1
Ortega, J. P. G., Ramón, S. M. Q., Panamá, J. C. P., Cajas, J. I. P., Pineda, E. G. R., Sacoto, E. P. L., Masache, G. A. R., Delgado, A. M. G., Calle, M. E. R., & Quizhpi, P. F. B. (2023) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.7702783
PIONEER PLUS: An Opportunity Knocking the Door for the Management of Diabesity
Mittal, N., & Bhadada, S. K. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0176
Advances in GLP-1 receptor agonists for the treatment of type 2 diabetes
Hong, S. (2023) · BIO Web of Conferences · doi:10.1051/bioconf/20236101006
Noronha, L. (2023) · Canadian Primary Care Today · doi:10.58931/cpct.2023.1s0717
The promise of a new orally active body weight reducer
Volpe, M., & Pedicino, D. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad470
Switching from subcutaneous to oral semaglutide in type 2 diabetes: A prospective study
Martínez‐Montoro, J. I., César, M. J. P., Generoso‐Piñar, M., Fernández‐Valero, A., Montalbán, Á. L., Simón‐Frapolli, V. J., Hernández‐Bayo, J., Pinzón‐Martín, J. L., & Tinahones, F. J. (2023) · Journal of Internal Medicine · doi:10.1111/joim.13737 · Cited by 1
Pleiotropic Benefits with Glucagon-like Peptide-1 Receptor Agonists: A Clinical Review
PATANGE, S. A., Singh, S. K., Bhattacharyya, S., Jagadeesha, A., Bhartia, M., Aneja, P., Hendral, A., & Chaudhuri, S. R. (2023) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_19_23
Non‐insulin Parenteral Therapies
Vilsbøll, T., Christensen, M., Andersen, A., & Knop, F. K. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch36
Rico-Fontalvo, J. E., Daza-Arnedo, R., Vázquez, L. C., Yánez, T. R., Raad-Sarabia, M., Toapanta, N., Rafael-Vicente, P., Montejo-Hernández, J. D., & Soler, M. J. (2024) · Nefrología Latinoamericana · doi:10.24875/nefro.m24000021
Rico-Fontalvo, J. E., Daza-Arnedo, R., Vázquez, L. C., Yánez, T. R., Raad-Sarabia, M., Toapanta, N., Rafael-Vicente, P., Montejo-Hernández, J. D., & Soler, M. J. (2024) · Nefrología Latinoamericana · doi:10.24875/nefro.23000052
Review of Efficacy and Safety of Semaglutide in the Management of Obesity
Han, S., & Park, T. E. (2024) · Korean Journal of Clinical Pharmacy · doi:10.24304/kjcp.2024.34.1.1
Semaglutide in the Treatment of Diabetes and Associated Obesity
Makuch, R., Chrościcka, A., Gała, K., Czajka, A., Lenard, P., Kucharski, A., Michalska, S., Pilarski, K., Dewicka, M., & Wawrzyniak, A. M. (2024) · Journal of Education Health and Sport · doi:10.12775/jehs.2024.73.51699
The efficacy of oral semaglutide in weight loss and glycemic control
Lopes, C. A., Lima, L. D. S., Eccard, J. V. A. A., & Gama, L. L. (2024) · International Journal of Health Science · doi:10.22533/at.ed.1594552414069
Makowska, K., Billewicz, M., Marczyk, A., & Lis, L. (2024) · Quality in Sport · doi:10.12775/qs.2024.20.54194
“Similarly, PIONEER 3 showed semaglutide outperforming sitagliptin at both 26 and 78 weeks [18].”
BackgroundWong, H. J., Sim, B., Teo, Y. H., Teo, Y. N., Chan, M. Y., Yeo, L. L. L., Eng, P. C., Tan, B. Y., Sattar, N. A., Dalakoti, M., et al. (2025) · doi:10.2337/figshare.27890331.v1
Efeitos do Orforglipron no tratamento da obesidade: revisão sistemática e metanálise
de Magalhães, M. J. D. S., de Souza, P. H. M., & Silva, V. T. O. F. (2025) · Bionorte · doi:10.47822/bn.v13i2.1045
Sind GLP-1-Rezeptor-Agonisten und SGLT2-Inhibitoren auch im höheren Lebensalter geeignet?
Stüdemann, S., & Engeli, S. (2025) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-2492-9440
The Emerging Trend of Managing Type 2 Diabetes with Oral Semaglutide
Bhattacharyya, S. (2025) · Clinical Diabetology · doi:10.5603/cd.105996
Sind GLP-1-Rezeptor-Agonisten und SGLT2-Inhibitoren auch im höheren Lebensalter geeignet?
Stüdemann, S., & Engeli, S. (2025) · Diabetes aktuell · doi:10.1055/a-2588-6338
Pharmacological targets in obesity
Pavli, P., Mastorakos, G. P., & Valsamakis, G. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27370-4.00013-5
Ormanac, K., Božek, T., Žuljević, K., Grbavac, J., Petrinović, M., Majanović, S. K., Canecki-Varžić, S., Berković, M. C., & Bilić-Čurčić, I. (2025) · Diabetology · doi:10.3390/diabetology6110127
Cardiovascular Effects of GLP-1 Analogues
Amoresano, L. (2025) · Springer eBooks · doi:10.1007/978-3-032-01700-0_15
Chakaroun, R. (2025) · Die Diabetologie · doi:10.1007/s11428-025-01389-9
Husain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Figshare · doi:10.6084/m9.figshare.13031555
Husain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Figshare · doi:10.6084/m9.figshare.13031567
Husain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Figshare · doi:10.6084/m9.figshare.13031546
Husain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Figshare · doi:10.6084/m9.figshare.13031564
Husain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Figshare · doi:10.6084/m9.figshare.13031558
Husain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Figshare · doi:10.6084/m9.figshare.13031549
Husain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Figshare · doi:10.6084/m9.figshare.13031561
Husain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Figshare · doi:10.6084/m9.figshare.13031552
Husain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Figshare · doi:10.6084/m9.figshare.13031570
Mosenzon, O., Capehorn, M. S., Remigis, A. D., Rasmussen, S., Weimers, P., & Rosenstock, J. (2022) · Figshare · doi:10.6084/m9.figshare.20882123
Self-citationKhawandanah, D. O., Alyamani, F. F., Almutairi, B. R., Almutairi, B. A., Alharbi, R. M., Alghanmi, S., Alsouri, M. T., & ALMUTAIRI, A. R. (2025) · Saudi Journal of Clinical Pharmacy · doi:10.4103/sjcp.sjcp_22_25 · Cited by 1
Documentation of Estimands and Reporting of Results
Li, H., Wright, M., & Fletcher, C. (2025) · Springer series in pharmaceutical statistics · doi:10.1007/978-3-032-02192-2_4
The ‘astounding’ rise of semaglutide — and what’s next for weight-loss drugs
Nogrady, B. (2026) · Nature · doi:10.1038/d41586-026-00228-1
Labate, A. M., Moretti, L., & Villari, P. (2026) · Endocrines · doi:10.3390/endocrines7010008
“…agonists (including subcutaneous semaglutide) have demonstrated robust glycaemic and weight effects; in head-to-head randomised evidence, oral semaglutide provides clinically meaningful HbA1c reductions, while subcutaneous formulations may achieve greater weight loss in some settings [9,15].”
Semaglutide in Metabolic Medicine: A Review on Clinical Applications and Emerging Therapeutics
Aljabri, A. A. (2026) · Saudi Medical Journal · doi:10.15537/1658-3175.1060
“…1, nausea, vomiting, and diarrhea were more frequent than in placebo, with early withdrawal linked to GI symptoms accounting for discontinuation rates of 2.3% at the 3 mg, 4.0% at the 7 mg, and 7.4% at the 14 mg doses, versus 2.2% with placebo, yet >90% of participants completed treatment [29].”
InfluentialHung, T.-H., Chen, C.-R., Hsu, C., Carvalho, A. F., Stubbs, B., Tseng, P., Wang, L., & Lin, P. (2026) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.70041
García, E. M., Tian, N., Alonso-Fernández, J.-R., Cai, X., Yang, D., Morante, J. J. H., & Sánchez, H. P. (2026) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6c01453
Nansereko, B., Wolbers, M., Carpenter, J. R., & Bartlett, J. W. (2026) · arXiv (Cornell University) · doi:10.48550/arxiv.2603.27010
“The design of our simulation study was adapted from Bell et al. [8], which in turn was modelled to reflect the structure of the PIONEER 1 trial [13].”
Dahan, A. E., Azran, C., & Dahan, A. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18040466
“To avoid decreased absorption, patients are instructed to administer the tablet once daily on an empty stomach, with a sip of water (up to half a glass of water, equivalent to 120 mL), and wait at least 30 min before eating or drinking or taking other oral medications [8,12,13].”
Liu, C., Hui, Q., Linchangco, G. V., Dabbs‐Brown, A., Zhou, J. J., Joseph, J., Reaven, P. D., Rhee, M. K., Djoussé, L., Cho, K., et al. (2026) · medRxiv · doi:10.64898/2026.04.10.26350615
González-Gálvez, G., Garnica-Cuéllar, J. C., Colín‐García, M. Á., Ferreira‐Hermosillo, A., Jimenez-Ramos, S. A., Contreras-Sandoval, A. Y., Cruz-Puente, P., & Duarte-Vega, M. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70219
Zaccardi, F., Aroda, V. R., Arslan, E. G., Bardtrum, L., Goldney, J., Ising, E., Priyadarshini, P., Slater, T., & Davies, M. J. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70770
Self-citationMihich, A., Caranti, S., & Verna, R. (2026) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-026-01421-9
Vázquez, S. M., Jiménez-Méndez, C., Asensio, A. P., Silva, E., Delgado, P. R., Fernández, L. G., Concellón, M. D. R. B., de la Mano, J. A. P., Vital, A. G., & Pérez, G. C. (2026) · Revista Clínica Española · doi:10.1016/j.rce.2026.502562
Răducu, L., Georgescu, D. E., Balcangiu‐Stroescu, A.-E., Chiperi, L. V., Văcăroiu, I. A., Bălan, D.-G., Georgescu, M. T., Mihai, D. A., Ignat, L. A., & Tipa, R. O. (2024) · OSF Preprints (OSF Preprints)
Metadata
- Authors
- Aroda, V. R., Rosenstock, J., Terauchi, Y., Altuntas, Y., Lalic, N. M., Morales Villegas, E. C., Jeppesen, O. K., Christiansen, E., Hertz, C. L., Haluzík, M., PIONEER 1 Investigators, Belkacem, K., Chiali, N., Bourezane, S., Guermaz, R., Popivanov, P., Lefterov, I., Tankova, T., Penchev, I., Koskova, M., Hudcova, M., Vesela, A., Rancova, A., Haluzik, M., Kiyosue, A., Matsuoka, O., Inoue, S., Terauchi, Y., Fukushima, Y., Ide, Y., Violante Ortiz, R. M., Morales Villegas, E., Golovach, A., Alpenidze, D., Frolova, E., Zhdanova, E., Ruyatkina, L., Ershova, O., Samoilova, Y., Zyangirova, S., Lalic, K., Lalic, N., Beljic Zivkovic, T., Ataoglu, E., Bakiner, O., Dayan, A., Sargin, M., Mert, M., Adas, M., Tabak, O., Altuntas, Y., Murray, A., Iranmanesh, A., Schlau, A., Wieskopf, B., Snyder, B., Griffin, C., Fogarty, C., Lovell, C., Allison, D., Fitz-Patrick, D., Grant, D., Klonoff, D., Williams, D., Armas, E., Palace, E., Ruoff, G., Martinez, G., Perez, G., Bays, H., Tatu, H., Maynard, J., Cedeno, J.-E., Aroda, V., Park, J., Sutton, J., Pouzar, J., Bertsch, J., Condit, J., Serje, J., Cabaccan, J., Risser, J., Frias, J., Rosenstock, J., Sivalingam, K., Maw, K., Hanson, L., Billings, L., Connery, L., Juarez, M., Lillestol, M., Fraser, N., Beckett, P., Wade, R., Gaona, R., Jackson, R., DeLuca, R., Alpizar, S., Herring, S., Stringam, S., Bauer, S., Gangi, S., Sligh, T., Jarrett, W., & Fitzgibbons, W.
- Affiliations
- Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
- Clinic for Endocrinology, Diabetes and Metabolic Diseases, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
- Cardiometabolic Research Center, Aguascalientes, Mexico
- Novo Nordisk (Denmark) (DK)
- Institute for Clinical and Experimental Medicine and Institute for Endocrinology, Prague, Czech Republic
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-06-11
- Volume
- 42
- Issue
- 9
- Pages
- 1724-1732
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2951522032
- Cited by
- 493
- References
- 23
- Citations by year
- 2026: 60 · 2025: 107 · 2024: 91 · 2023: 56 · 2022: 53 · 2021: 55 · 2020: 57 · 2019: 13
- FWCI
- 36.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- oral semaglutide, type 2 diabetes, GLP-1 receptor agonists, monotherapy, HbA1c, glycemic control, weight loss, treatment policy estimand, gastrointestinal adverse effects, drug discontinuation, dose comparison, treatment efficacy and safety
- MeSH terms
- Semaglutide, Administration, Oral, Adult, Diabetes Mellitus, Type 2, Diet, Double-Blind Method, Glucagon-Like Peptides, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Weight Loss, Exercise
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.